Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Guilin compound (also known as Gui Ling He Ji) is a traditional Chinese herbal medicine formulation being investigated as an adjuvant treatment for ovarian hyperstimulation syndrome (OHSS). Developed by researchers at the Beijing Obstetrics and Gynecology Hospital, the compound is typically used in Traditional Chinese Medicine (TCM) to promote blood circulation, resolve blood stasis, and facilitate diuresis. In the context of OHSS, it is intended to reduce clinical risks such as fluid accumulation and enlarged ovarian volume by modulating vascular permeability and inflammatory responses. The formulation is often derived from classical TCM prescriptions such as Gui Zhi Fu Ling Wan, which contains ingredients like *Cinnamomi Ramulus* and *Poria*.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Guilin compound.